Results 81 to 90 of about 27,935 (169)

Reassessing the Conduct of Patch Clamp Cardiac Ion Channel Assays to Improve Nonclinical Data Translation to Clinical ECG Changes and Proarrythmia Risk. [PDF]

Clin Transl Sci
Alvarez Baron C, Zhao J, Guo D, Mistry S, De Palma R, Ismaiel OA, Wu WW.   +6 more
europepmc   +1 more source

Oral Lamivudine for Extended HIV Postnatal Prophylaxis. [PDF]

Paediatr Drugs
Van de Perre P, Meda N, Tassembedo S, Moles JP, Kankasa C, Mennecier A, Mwiya M, Nagot N, Tylleskär T.   +8 more
europepmc   +1 more source

Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement. [PDF]

J Infect Dis
Perazzolo S, Flexner CW, Stephen ZR, Acosta EP, Bender Ignacio RA, Ho RJY.   +5 more
europepmc   +1 more source

COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review. [PDF]

BMC Infect Dis
Bosquet A, Affo C, Happe F, Helfer H, Versini E, Mahé I.   +5 more
europepmc   +1 more source

Predictive performance and QSPR analysis of SARS-CoV-2 and tuberculosis drugs using distance-based topological descriptors. [PDF]

Sci Rep
Supriya, Iyer RR.
europepmc   +1 more source

Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Pattern Recognition Algorithms in Pharmacogenomics and Drug Repurposing-Case Study: Ribavirin and Lopinavir. [PDF]

Pharmaceuticals (Basel)
Calvo H, Islas-Díaz D, Hernández-Laureano E.   +2 more
europepmc   +1 more source

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV. [PDF]

Antimicrob Agents Chemother
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE, CHAPAS-4 trial team.   +17 more
europepmc   +1 more source

Tolerability of lopinavir versus dolutegravir in children and adolescents with HIV. [PDF]

AIDS
Blankenberger J, Devendra A, Bakaya M, Lee T, Steffy TLF, Makhesi T, Gilbride CJ, Belus JM, Thahane L, Tschumi N, Marake NB, Tarumbiswa T, Huber R, Chammartin F, Labhardt ND, Brown JA.   +15 more
europepmc   +1 more source

Timeliness of switching to second-line antiretroviral therapy following virologic failure in Dar es Salaam, Tanzania. [PDF]

BMC Res Notes
Thadeo MH, Bwire GM.
europepmc   +1 more source